Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug and medical ...
Stakeholders responding to recent draft guidance from the US Food and Drug Administration (FDA) on the use of minimal ...
Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug and medical device regulation, and what we’re reading from around the web. This week, ...
The US Food and Drug Administration (FDA) and the generic drug industry have reached agreement on some areas amid negotiations to reauthorize the Generic Drug User Fee Amendments (GDUFA IV) program, ...
Regulatory Recon is our regular intelligence briefing for the regulatory affairs space, bringing you the top regulatory, ...
The European Medicines Agency has finalized its reflection paper on a tailored clinical approach to biosimilar development, ...
The US Food and Drug Administration (FDA) and the generic drug industry have reached agreement on some areas amid ...
The US Food and Drug Administration (FDA) has cited a medical device manufacturer and a contract drug testing laboratory for ...
AI drug developer Insilico Medicine and Lilly ink commercialization deal worth up to $2.75 billion ( STAT) AstraZeneca’s in ...
A reviewer-informed discussion on managing regulatory submissions across their full lifecycle—from assembly through health authority review—focusing on clarity, traceability, and change management.
Recon: Novo to offer discount Wegovy subscription for self-pay US consumers; Lilly to acquire Centessa in deal worth up to $7.8B Join one of the many groups where you can pursue your regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results